MoonLake Immunotherapeutics (MLTX)

14.06 -0.56 (-3.80%) USD  |  NASDAQ  |  Dec 11, 16:00
14.06 0.00 (0.00%) After-Hours: 20:00
More

MoonLake Immunotherapeutics Debt to Equity Ratio: 0.2621 for Sept. 30, 2025

Debt to Equity Ratio Chart

View Debt to Equity Ratio for MLTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Debt to Equity Ratio Definition

View Debt to Equity Ratio Definition
Start Trial

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Baxter International, Inc. 1.341
aTyr Pharma, Inc. 0.154
BeOne Medicines Ltd. 0.4613
Merus NV 0.0159
AC Immune SA 0.0746

Debt to Equity Ratio Related Metrics

Total Assets (Quarterly) 414.34M
Total Liabilities (Quarterly) 123.14M
Shareholders Equity (Quarterly) 288.91M
Current Ratio 8.502
Net Debt Paydown Yield -3.17%